Cargando…

Association between antibiotics use and outcome in patients with NSCLC treated with immunotherapeutics

Detalles Bibliográficos
Autores principales:	Huemer, F, Rinnerthaler, G, Lang, D, Hackl, H, Lamprecht, B, Greil, R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6879001/ https://www.ncbi.nlm.nih.gov/pubmed/30689705 http://dx.doi.org/10.1093/annonc/mdz021

Ejemplares similares

Sex-Based Clinical Outcome in Advanced NSCLC Patients Undergoing PD-1/PD-L1 Inhibitor Therapy—A Retrospective Bi-Centric Cohort Study
por: Lang, David, et al.
Publicado: (2021)

Baseline Absolute Lymphocyte Count and ECOG Performance Score Are Associated with Survival in Advanced Non-Small Cell Lung Cancer Undergoing PD-1/PD-L1 Blockade
por: Huemer, Florian, et al.
Publicado: (2019)

Impact of antibiotic treatment on immune-checkpoint blockade efficacy in advanced non-squamous non-small cell lung cancer
por: Huemer, Florian, et al.
Publicado: (2018)

Hospitalizations and Clinical Outcome in Metastatic Colorectal Cancer During Regorafenib or TAS-102 Therapy
por: Huemer, Florian, et al.
Publicado: (2020)

Immunotherapeutic Advances for NSCLC
por: Massafra, Marco, et al.
Publicado: (2021)

Association between radiation pneumonitis and tumor response in patients with NSCLC treated with chemoradiation
por: MacManus, Michael P, et al.
Publicado: (2014)

Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study
por: Lang, David, et al.
Publicado: (2019)

The association between pulmonary embolism and the cancer-related genomic alterations in patients with NSCLC
por: Xiong, Wei, et al.
Publicado: (2020)

APOBEC3 signature mutations in chronic lymphocytic leukemia
por: Rebhandl, S, et al.
Publicado: (2014)

Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial
por: Rinnerthaler, Gabriel, et al.
Publicado: (2020)

When Antibiotics Treat Heart Block
por: Lama, Loveena, et al.
Publicado: (2012)

Is machine learning-based assessment of tumor-infiltrating lymphocytes on standard histologic images associated with outcomes of immunotherapy in patients with NSCLC?
por: Inamura, Kentaro, et al.
Publicado: (2023)

Identification of the prognostic and immunotherapeutic potential of L antigen family member 3 in malignant pleural mesothelioma
por: Dong, Xubin, et al.
Publicado: (2020)

Chemotherapy and quality of life in advanced NSCLC
por: Farrugia, D, et al.
Publicado: (2001)

Comparison between FDG-PET/CT and bone scan in bone metastasis from NSCLC
por: Tamura, Tomohiro, et al.
Publicado: (2014)

Combination Strategies for Immune-Checkpoint Blockade and Response Prediction by Artificial Intelligence
por: Huemer, Florian, et al.
Publicado: (2020)

Evidence for PDGFRA, PDGFRB and KIT deregulation in an NSCLC patient
por: Negri, T, et al.
Publicado: (2007)

Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie)
por: Huemer, Florian, et al.
Publicado: (2018)

Chemotherapy and quality of life in advanced NSCLC – reply
por: Anderson, Heather, et al.
Publicado: (2001)

Human Vaccines & Immunotherapeutics: News
por: Riedmann, Eva M.
Publicado: (2013)

Hematogenous muscular metastasis of NSCLC in FDG-PET/CT
por: Satoh, Hiroaki, et al.
Publicado: (2015)

CHEK2 Pathogenic Germline Variants in Patients With NSCLC
por: Sorscher, Steven
Publicado: (2022)

Development and validation of a mutation-based model to predict immunotherapeutic efficacy in NSCLC
por: He, Ping, et al.
Publicado: (2023)

Streptococcus bovis infectious endocarditis and occult gastrointestinal neoplasia: experience with 25 consecutive patients treated surgically
por: Alozie, Anthony, et al.
Publicado: (2015)

Osimertinib in combination with bevacizumab in EGFR-Mutated NSCLC with leptomeningeal metastases
por: Jiang, Tao, et al.
Publicado: (2020)

Infection of Helicobacter cinaedi Should Be Treated for an Adequate Duration with Combined Antibiotic Therapy
por: Fukuchi, Takahiko, et al.
Publicado: (2019)

The negative relationship between patients with NSCLC harbored STK11/KEAP1 copy number variation and immune microenvironment infiltration
por: Zhang, Chenyue
Publicado: (2021)

Extracellular vesicle-derived DNA for performing EGFR genotyping of NSCLC patients
por: Hur, Jae Young, et al.
Publicado: (2018)

Comment on ‘Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab’
por: Shimokawa, H, et al.
Publicado: (2011)

High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status
por: Cortellini, Alessio, et al.
Publicado: (2022)

The clinical utility of dynamic ctDNA monitoring in inoperable localized NSCLC patients
por: Yang, Yin, et al.
Publicado: (2022)

The Addition of Prophylactic Antibiotics Can Achieve a Favorable Outcome
por: Fukuchi, Takahiko, et al.
Publicado: (2019)

Sustained response to brigatinib in a patient with refractory metastatic pheochromocytoma harboring R1192P anaplastic lymphoma kinase mutation: a case report from the Austrian Group Medical Tumor Therapy next-generation sequencing registry and discussion of the literature
por: Heregger, R., et al.
Publicado: (2021)

Immunotherapeutic Approaches for Treating Hepatocellular Carcinoma
por: Shen, Wanying, et al.
Publicado: (2022)

Infection of Helicobacter cinaedi Should Be Treated for an Adequate Duration with Combined Antibiotic Therapy: Author's Reply
por: Fujita, Shunichi, et al.
Publicado: (2019)

Identification and Validation of Immune-Related Long Non-Coding RNA Signature for Predicting Immunotherapeutic Response and Prognosis in NSCLC Patients Treated With Immunotherapy
por: Ma, Jianli, et al.
Publicado: (2022)

Human Vaccines & Immunotherapeutics awards Top Reviewer of the Year
por: Ellis, Ronald, et al.
Publicado: (2014)

Human Vaccines & Immunotherapeutics awards Top Reviewer of the Year
por: Ellis, Ronald, et al.
Publicado: (2013)

Crizotinib: aseptic abscesses in multiple organs during treatment of EML4-ALK-positive NSCLC
por: Weber, Daniel, et al.
Publicado: (2021)

Response to ‘Clinical outcomes in NSCLC patients with EGFR mutations: pooled analysis’ (Paz-Ares et al., J Cell Mol Med. 2010; 14: 51–69)
por: Watkins, Claire, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_914k18vfs30g4491m1r6ngio6h